Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: API Import to Russia (February 2018)

Thursday, April 19, 2018

Between January and February 2018, Russia imported 14.9 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms 45% higher than that of the same period of 2017. In physical terms, Russia imported 1,760,000 tons of APIs, which is 9% higher than that of the same period of 2017.

The period follows the 2017 trend, when the API import dynamics were 22% and 5.3% in monetary and physical terms, respectively.

The API import in February 2018 doubled that of February 2017 in monetary terms, which pushed the trend. In February 2018, Russia imported 10.1 bln RUB worth of APIs (free circulation prices, VAT included), which is nearly 900 tons (0.4% lower than that of February 2017), while the dynamics in January 2018 were more than 18%.

In February, the average price was more than twice as high as in January – the price for 1 kg was 11,300 RUB, which is due to the new import list. In particular, Russia imported 261 names of APIs, and nearly half of them (128 names) were not imported in February 2017. The imports of Pneumococcal monovalent polysaccharide conjugates, Perindopril erbumine, Dipyridamolum, and Actovegin showed the best dynamics, with a 2, 7.8, 12, and 3.5 times increase, respectively.